Uterine Myomas and Treatments
Uterine Myomas and Treatments is a research topic within Obstetrics and Gynecology. Science Explorer counts 34k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on various aspects of uterine conditions and their treatments, including uterine leiomyoma (fibroids), hysterectomy, uterine sarcomas, uterine artery embolization, reproductive outcomes after different treatments, MRI guidance for treatment, the role of progesterone, and the impact on health-related quality of life. The cluster also covers epidemiological studies related to uterine conditions.
- Uterine Leiomyoma
- Uterine Fibroids
- Hysterectomy
- Uterine Sarcomas
- Uterine Artery Embolization
- Reproductive Outcomes
- MRI Guidance
- Progesterone Action
- Health-related Quality of Life
- Epidemiology
- Research works
- 34k fractional, since 1950
- In the world top 10%
- 3.4k per year above
- Top-10% rate
- 10.0% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- +8% the tick is no change
- Largest producer
United States
32% of the 10 largest, 2022-now
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Uterine Myomas and Treatments research?
By volume, the United States and China publish the most (1.5k and 976 works in 2022-now).
By volume, 2022-now
- 1
United States 1.5k works
- 2
China 976 works
- 3
India 646 works
- 4
Japan 324 works
- 5
Italy 277 works
- 6
Türkiye 229 works
- 7
United Kingdom 225 works
- 8
Germany 167 works
- 9
Spain 165 works
- 10
Russia 163 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Uterine Myomas and Treatments research?
By volume in 2022-now, All India Institute of Medical Sciences publishes the most Uterine Myomas and Treatments research, followed by Mayo Clinic and Harvard University.
By volume, 2022-now
- 1
All India Institute of Medical Sciences
India 59 works
- 2
Mayo Clinic
United States 56 works
- 3
Harvard University
United States 56 works
- 4
Sichuan University
China 51 works
- 5
Johns Hopkins University
United States 32 works
- 6
Cleveland Clinic
United States 31 works
- 7
Capital Medical University
China 30 works
- 8
Obstetrics and Gynecology Hospital of Fudan University
China 29 works
- 9
University of Toronto
Canada 29 works
- 10
Chongqing Medical University
China 28 works
Who are the leading researchers in Uterine Myomas and Treatments?
The most-cited researchers publishing on Uterine Myomas and Treatments include Walter Churchill Willett, Trevor Hastie and Salim Yusuf.
- 1
Walter Churchill Willett
United States 411k citations
- 2
Trevor Hastie
United States 301k citations
- 3
Salim Yusuf
Canada 294k citations
- 4
Patrick M. Bossuyt
Netherlands 270k citations
- 5
Gordon Brent Mills
United States 265k citations
- 6
JoAnn E. Manson
United States 263k citations
- 7
Carlo La Vecchia
Italy 258k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Uterine Myomas and Treatments research done?
The largest centres of Uterine Myomas and Treatments research in 2022-now are Beijing (China), Shanghai (China), New York (United States) and London (United Kingdom).
Where is the best place to study Uterine Myomas and Treatments?
Among universities, judged by research, Università Cattolica del Sacro Cuore, Harvard University and Chongqing Medical University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Uterine Myomas and Treatments, country by countryIs Uterine Myomas and Treatments research growing?
Output in 2022-2025 was 8% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Uterine Myomas and Treatments.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Uterine Myomas and Treatments as a percentage of every work published that year, 0.029% in 2024.
Fractional works of Uterine Myomas and Treatments over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Uterine Myomas and Treatments. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.